Everolimus as cancer therapy: Cardiotoxic or an unexpected antiatherogenic agent? A narrative review.

Autor:	Karvelas G; Oncology Unit of the 3(rd) Internal Medicine Clinic, Sotiria General Hospital, Athens Medical School, Greece., Roumpi A; Oncology Unit of the 3(rd) Internal Medicine Clinic, Sotiria General Hospital, Athens Medical School, Greece. Electronic address: aroumpi@yahoo.com., Komporozos C; 2(nd) Cardiology Department, Athens Naval Hospital, Greece., Syrigos K; Oncology Unit of the 3(rd) Internal Medicine Clinic, Sotiria General Hospital, Athens Medical School, Greece.
Jazyk:	angličtina
Zdroj:	Hellenic journal of cardiology : HJC = Hellenike kardiologike epitheorese [Hellenic J Cardiol] 2018 Jul - Aug; Vol. 59 (4), pp. 196-200. Date of Electronic Publication: 2018 Mar 29.
DOI:	10.1016/j.hjc.2018.01.013
Abstrakt:	Everolimus (EVE) is now approved by many agencies for the treatment of variable neoplasms. The risk for adverse events with this agent is not adequately defined. The purpose of this review is to summarize the EVE-induced cardiotoxic effect as an antineoplastic factor on patients who received the specific drug and to evaluate any possible antiatherogenic effects due to systemic use of the drug. Articles were searched on PubMed until August 2017. Articles included an expanded-access clinical trial, as well as phase 2 or 3 clinical trials (most of them were randomized). Three experimental studies that provided evidence for the possible antiatherogenic action of EVE were also included. In addition, only studies that evaluated the systemic use of the drug were included. To be eligible for inclusion, trials should have evaluated patients with malignancy, treated by EVE, or assessed the antiatherogenic effect of the systemic use of EVE through clinical or experimental studies. Only articles written in English language were included. No direct cardiotoxic adverse effects (arrhythmia, acute coronary event, heart failure, and echocardiography pathologic findings) were reported. Patients appeared to have a risk of developing adverse events that could be associated with the risk factors of cardiovascular disease. In all clinical studies, patients suffered hyperglycemia, and in most of them, hyperlipidemia was observed. Fewer studies have reported the incidence of hypertension. Finally, there is evidence claiming that EVE has an antiatherogenic action. Three experimental studies have shown that the systemic use of EVE in mice or rabbits with atherosclerotic lesions led to the reduction in atheromatous plaque growth. However, we could not find any clinical study that showed similar results in patients with cancer. To sum up, the only reported cardiac adverse event of EVE treatment in patients with cancer is indirect. They are associated with the risk factors of cardiovascular disease (hyperglycemia, hyperlipidemia, and hypertension), which are mainly mild and easily manageable. Further research and data that support the antiatherogenic action of EVE are needed. (Copyright © 2018 Hellenic Society of Cardiology. Published by Elsevier B.V. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu